30 closest matches · ranked by relevance
Variceal Bleeding, Cirrhosis
Primary: 5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death) — 218; 216; 225 participants
Liver Cirrhosis · Hypertension, Portal
Primary: Variceal Bleeding Events — 3; 3 Participants
Esophageal and Gastric Varices
Primary: Rebleeding From Gastric Varices — 14; 21 Participants
Variceal Bleeding
Primary: Proportion of Patients With Eradication of Esophageal Varices — 37; 23 Participants
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants
Ascites · Cirrhosis
Primary: Time to Recurrence of Ascites. — 10; 8 days — p=<0.05
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
Chronic Liver Disease
Primary: Disease Severity Index (DSI) Less Than/Equal to 18.3 to Rule Out Large Varices — 33; 3; 171; 68 Participants
Bleeding Peptic Ulcer
Primary: Rate of Clinically Significant Rebleeding Within 72 Hours — 107; 101; 1; 6 participants
Bleeding Peptic Ulcer
Primary: Number of Participants With Rebleeding — 3; 4 Participants
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
Gastrointestinal Bleeding
Primary: Rebleeding Rate — 97 participants
Liver Cirrhosis · Hepatic Cirrhosis · Portal Hypertension
Primary: Hepatic Venous Pressure Gradient (HVPG) — 15.2; 8.05; 20.62; 14.1 mmHg — p=0.257
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization — 48; 24 participants with hemostatic success — p=<.0001
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
Obscure Gastrointestinal Bleeding · Angiodysplasia · Gastric Antral Vascular Ectasia
Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants
Gastrointestinal Hemorrhage
Primary: Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo — 22; 40 Participants
Portal Hypertension · Liver Cirrhosis
Primary: Safety (Incidence and Severity of Adverse Events) — 23; 2 Number of adverse events
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.2; 92.2 Percentage of participants — p=<0.001
Gastro Intestinal Bleeding · Hematemesis · Melena
Primary: Rate of Detection of Bleeding — 11; 11 Participants
Bleeding Peptic Ulcers
Primary: Re-bleeding Within 4 Weeks — 3; 1 Participants
Stress Ulcer Prophylaxis
Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393
Cirrhosis · Healthy
Primary: Number of Patients With Overgrowth of Oral Microbiota in Their Stool After PPI Therapy Withdrawal or Initiation — 45; 15 Participants
Clinically Significant Portal Hypertension
Primary: Patients With Change in HVPG From Baseline — 1; 1 participants
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes